265 related articles for article (PubMed ID: 33812919)
1. Advances in receptor modulation strategies for flexible, efficient, and enhanced antitumor efficacy.
Wang DD; Zhang XN
J Control Release; 2021 May; 333():418-447. PubMed ID: 33812919
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in dual-ligand targeted nanocarriers for cancer therapy.
Khan N; Ruchika ; Dhritlahre RK; Saneja A
Drug Discov Today; 2022 Aug; 27(8):2288-2299. PubMed ID: 35439614
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
4. The significance of transferrin receptors in oncology: the development of functional nano-based drug delivery systems.
Tortorella S; Karagiannis TC
Curr Drug Deliv; 2014; 11(4):427-43. PubMed ID: 24387131
[TBL] [Abstract][Full Text] [Related]
5. Receptor mediated tumor targeting: an emerging approach for cancer therapy.
Mohanty C; Das M; Kanwar JR; Sahoo SK
Curr Drug Deliv; 2011 Jan; 8(1):45-58. PubMed ID: 21034422
[TBL] [Abstract][Full Text] [Related]
6. Actively targeted nanocarriers for drug delivery to cancer cells.
Biffi S; Voltan R; Bortot B; Zauli G; Secchiero P
Expert Opin Drug Deliv; 2019 May; 16(5):481-496. PubMed ID: 30955393
[TBL] [Abstract][Full Text] [Related]
7. Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy.
Vaghasiya K; Ray E; Singh R; Jadhav K; Sharma A; Khan R; Katare OP; Verma RK
Mater Sci Eng C Mater Biol Appl; 2021 Apr; 123():112027. PubMed ID: 33812642
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Effect of surface ligand modification on the properties of anti-tumor nanocarrier.
Ying N; Lin X; Xie M; Zeng D
Colloids Surf B Biointerfaces; 2022 Dec; 220():112944. PubMed ID: 36274398
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.
Kebebe D; Liu Y; Wu Y; Vilakhamxay M; Liu Z; Li J
Int J Nanomedicine; 2018; 13():1425-1442. PubMed ID: 29563797
[TBL] [Abstract][Full Text] [Related]
11. Actively Targeted Nanoparticles for Drug Delivery to Tumor.
Bi Y; Hao F; Yan G; Teng L; Lee RJ; Xie J
Curr Drug Metab; 2016; 17(8):763-782. PubMed ID: 27335116
[TBL] [Abstract][Full Text] [Related]
12. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
13. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.
Shi P; Cheng Z; Zhao K; Chen Y; Zhang A; Gan W; Zhang Y
J Nanobiotechnology; 2023 Mar; 21(1):103. PubMed ID: 36944946
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in active targeting of nanomaterials for anticancer drug delivery.
Dutta B; Barick KC; Hassan PA
Adv Colloid Interface Sci; 2021 Oct; 296():102509. PubMed ID: 34455211
[TBL] [Abstract][Full Text] [Related]
15. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
16. An updated review of folate-functionalized nanocarriers: A promising ligand in cancer.
Ebrahimnejad P; Sodagar Taleghani A; Asare-Addo K; Nokhodchi A
Drug Discov Today; 2022 Feb; 27(2):471-489. PubMed ID: 34781032
[TBL] [Abstract][Full Text] [Related]
17. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery.
van Vlerken LE; Vyas TK; Amiji MM
Pharm Res; 2007 Aug; 24(8):1405-14. PubMed ID: 17393074
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems.
Ying M; Chen G; Lu W
Curr Pharm Des; 2015; 21(22):3066-75. PubMed ID: 26027578
[TBL] [Abstract][Full Text] [Related]
19. Surface engineered nanocarriers for the management of breast cancer.
Nitheesh Y; Pradhan R; Hejmady S; Taliyan R; Singhvi G; Alexander A; Kesharwani P; Dubey SK
Mater Sci Eng C Mater Biol Appl; 2021 Nov; 130():112441. PubMed ID: 34702526
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in drug delivery systems for enhancing drug penetration into tumors.
He B; Sui X; Yu B; Wang S; Shen Y; Cong H
Drug Deliv; 2020 Dec; 27(1):1474-1490. PubMed ID: 33100061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
